DNA Ginkgo Bioworks Holdings Inc
Price (delayed)
$7.55
Market cap
$419.59M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$18.4
Enterprise value
$141.49M
the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline
Highlights
DNA's gross margin is up by 13% year-on-year
The EPS rose by 31% year-on-year but it has declined by 4.5% since the previous quarter
The net income has grown by 27% YoY but it has contracted by 5% from the previous quarter
The debt has soared by 93% since the previous quarter and by 10% year-on-year
The equity is down by 45% year-on-year and by 16% since the previous quarter
Key stats
What are the main financial stats of DNA
Market
Valuations
Earnings
Shares outstanding
55.58M
Market cap
$419.59M
Enterprise value
$141.49M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.5
Price to sales (P/S)
2.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.77
Revenue
$184.34M
EBIT
-$897.58M
EBITDA
-$807.95M
Free cash flow
-$344.91M
Per share
Balance sheet
Liquidity
EPS
-$18.4
Free cash flow per share
-$6.71
Book value per share
$15.07
Revenue per share
$3.59
TBVPS
$29.87
Total assets
$1.63B
Total liabilities
$792.18M
Debt
$452.27M
Equity
$833.07M
Working capital
$617.21M
Debt to equity
0.54
Current ratio
4.71
Quick ratio
4.51
Net debt/EBITDA
0.34
Margins
Efficiency
Dividend
EBITDA margin
-438.3%
Gross margin
80.2%
Net margin
-487%
Operating margin
-469.5%
Return on assets
-52%
Return on equity
-86.1%
Return on invested capital
-103.4%
Return on capital employed
-61.5%
Return on sales
-486.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DNA stock price
How has the Ginkgo Bioworks Holdings stock price performed over time
Intraday
10.87%
1 week
20.99%
1 month
-14.79%
1 year
-89.8%
YTD
-88.83%
QTD
-43.53%
Financial performance
How have Ginkgo Bioworks Holdings's revenue and profit performed over time
Revenue
$184.34M
Gross profit
$147.88M
Operating income
-$865.46M
Net income
-$897.68M
Gross margin
80.2%
Net margin
-487%
The revenue has declined by 43% year-on-year and by 12% since the previous quarter
The gross profit has declined by 36% year-on-year and by 12% since the previous quarter
DNA's operating income is up by 33% year-on-year but it is down by 4.7% since the previous quarter
The net margin is down by 30% year-on-year and by 19% since the previous quarter
Growth
What is Ginkgo Bioworks Holdings's growth rate over time
Valuation
What is Ginkgo Bioworks Holdings stock price valuation
P/E
N/A
P/B
0.5
P/S
2.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.77
The EPS rose by 31% year-on-year but it has declined by 4.5% since the previous quarter
The price to book (P/B) is 81% lower than the last 4 quarters average of 2.4
The equity is down by 45% year-on-year and by 16% since the previous quarter
The stock's price to sales (P/S) is 81% less than its last 4 quarters average of 9.8
The revenue has declined by 43% year-on-year and by 12% since the previous quarter
Efficiency
How efficient is Ginkgo Bioworks Holdings business performance
The return on sales has declined by 28% year-on-year and by 19% since the previous quarter
The ROE has contracted by 22% from the previous quarter and by 11% YoY
The company's return on assets fell by 15% QoQ but it rose by 3.2% YoY
The company's return on invested capital rose by 11% YoY but it fell by 11% QoQ
Dividends
What is DNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DNA.
Financial health
How did Ginkgo Bioworks Holdings financials performed over time
Ginkgo Bioworks Holdings's total assets is 105% higher than its total liabilities
Ginkgo Bioworks Holdings's current ratio has decreased by 37% YoY and by 12% from the previous quarter
DNA's quick ratio is down by 37% year-on-year and by 12% since the previous quarter
The debt is 46% smaller than the equity
The debt to equity has soared by 125% from the previous quarter and by 100% YoY
The debt has soared by 93% since the previous quarter and by 10% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.